Next Level Private LLC Acquires 6,214 Shares of Pfizer Inc. (NYSE:PFE)

Next Level Private LLC raised its holdings in shares of Pfizer Inc. (NYSE:PFE) by 13.1% during the fourth quarter, Holdings Channel reports. The fund owned 53,772 shares of the biopharmaceutical company’s stock after buying an additional 6,214 shares during the period. Next Level Private LLC’s holdings in Pfizer were worth $1,548,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of PFE. RB Capital Management LLC grew its position in Pfizer by 6.7% during the first quarter. RB Capital Management LLC now owns 5,446 shares of the biopharmaceutical company’s stock valued at $282,000 after acquiring an additional 341 shares during the last quarter. Ironwood Wealth Management LLC. grew its holdings in shares of Pfizer by 1.1% in the first quarter. Ironwood Wealth Management LLC. now owns 36,081 shares of the biopharmaceutical company’s stock worth $1,868,000 after purchasing an additional 400 shares during the last quarter. United Bank increased its stake in shares of Pfizer by 0.6% in the first quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock worth $2,416,000 after buying an additional 290 shares during the period. Ergoteles LLC raised its holdings in Pfizer by 136.3% during the 1st quarter. Ergoteles LLC now owns 36,766 shares of the biopharmaceutical company’s stock valued at $1,903,000 after buying an additional 21,209 shares during the last quarter. Finally, Mackenzie Financial Corp raised its holdings in Pfizer by 6.4% during the 1st quarter. Mackenzie Financial Corp now owns 1,337,418 shares of the biopharmaceutical company’s stock valued at $69,238,000 after buying an additional 79,887 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Price Performance

PFE opened at $27.78 on Thursday. The stock has a 50-day moving average price of $27.47 and a 200-day moving average price of $29.47. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. The firm has a market cap of $157.31 billion, a PE ratio of 77.14, a P/E/G ratio of 1.24 and a beta of 0.61. Pfizer Inc. has a 1 year low of $25.61 and a 1 year high of $42.22.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The firm had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. During the same quarter in the previous year, the firm earned $1.14 EPS. Pfizer’s quarterly revenue was down 41.3% compared to the same quarter last year. Sell-side analysts predict that Pfizer Inc. will post 2.22 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

PFE has been the subject of a number of recent analyst reports. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Truist Financial cut their target price on shares of Pfizer from $42.00 to $36.00 and set a “buy” rating on the stock in a research note on Thursday, December 14th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research note on Friday, March 1st. TD Cowen downgraded Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective for the company. in a report on Thursday, January 4th. Finally, Guggenheim began coverage on Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 price objective for the company. Twelve analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, Pfizer presently has an average rating of “Hold” and a consensus target price of $36.88.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.